Literature DB >> 18975088

Hepatitis C virus and inflammatory bowel disease.

Todd L Horn1, Joel Reynolds, Willem de Villiers, Luis R Peña.   

Abstract

Gastroenterologists frequently treat patients with complex illnesses such as chronic hepatitis C infections and inflammatory bowel disease (IBD). Occasionally, a patient will present with these two diseases which behave very differently and the treatment for one may potentially exacerbate the other. The purpose of this article is to review the current literature regarding hepatitis C virus therapy in the setting of IBD as well as the effects of common IBD therapies on the hepatitis C virus. Based on limited data, anti-viral therapy is probably safe in patients with well-controlled IBD, but there might be a risk of causing new onset of IBD. Also, it does not appear that the commonly used medications for IBD have much of an effect on the hepatitis C virus (HCV) or its course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18975088     DOI: 10.1007/s10620-008-0489-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  42 in total

1.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

Authors:  P Ostuni; C Botsios; L Punzi; P Sfriso; S Todesco
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

2.  Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis.

Authors:  R Sprenger; M Sagmeister; F Offner
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Masaru Shimamoto; Yoshihiro Miyanaka; Toru Hiyama; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Masaharu Sumii; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

4.  Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients.

Authors:  Leonardo L Schiavon; Roberto J Carvalho-Filho; Janaína L Narciso-Schiavon; Denize V Barbosa; Valéria P Lanzoni; Maria Lucia G Ferraz; Antonio Eduardo B Silva
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

5.  Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.

Authors:  S Bargiggia; D Thorburn; A Anderloni; S Ardizzone; A Giorgi; G Bianchi Porro; F Parente
Journal:  Aliment Pharmacol Ther       Date:  2005-08-01       Impact factor: 8.171

6.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.

Authors:  M Y Mok; W L Ng; M F Yuen; R W Wong; C S Lau
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

7.  [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].

Authors:  F Longo; X Hebuterne; A Tran; P Staccini; P Hastier; S Schneider; S Benzaken; C Tirtaine; P Rampal
Journal:  Gastroenterol Clin Biol       Date:  2000-01

8.  Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.

Authors:  Frank A Parke; John D Reveille
Journal:  Arthritis Rheum       Date:  2004-10-15

9.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Authors:  H Tilg; H Vogelsang; O Ludwiczek; H Lochs; A Kaser; J-F Colombel; H Ulmer; P Rutgeerts; S Krüger; A Cortot; G D'Haens; M Harrer; C Gasche; F Wrba; I Kuhn; W Reinisch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

10.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  2 in total

Review 1.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 2.  The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Authors:  Ming Valerie Lin; Wojciech Blonski; Anna M Buchner; K Rajender Reddy; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-11-20       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.